Covishield and COVAXIN Approved for Regular Market

Story Highlights
  • Drug regulator for India approved market sale of indigenous vaccines.
  • Both the vaccines would be priced at Rs 275 per dose.
  • The vaccines can be procured at the hospitals and clinics.

New Delhi: The Drug regulator for India approved the sale of Covishield and COVAXIN in the market, a close source said. Apparently, the vaccines can be purchased by the public at hospitals and clinics. A quotation by the drug regulator is stated to have fixed the pricing of each dose at Rs 275 with an additional service charge of Rs 150.

The approval was granted under the New Drugs and Clinical Trials Rules 2019. Under the terms, the firms are mandated to submit data of the clinical trials and the vaccines to be supplied.

Heads at the vaccine manufacturers of both the firms had earlier approached the DCGI. Prakash Kumar Singh and Krishna Mohan from SII and Bharat Biotech had written seeking regular market authorization for Covishield and COVAXIN respectively. Both the vaccines were granted EUA on January 3rd after a slew of documents were verified by the drug controllers.

Related Articles

Back to top button